Literature DB >> 21569053

Supervised disulfiram in the treatment of alcohol use disorder: a commentary.

Henning Krampe, Claudia D Spies, Hannelore Ehrenreich.   

Abstract

BACKGROUND: This commentary discusses the systematic review "The efficacy of disulfiram for the treatment of alcohol use disorder (AUD)" by Jørgensen and colleagues (2011, Alcohol Clin Exp Res DOI: 10.1111/j.1530-0277.2011.01523.x). The main focus of the commentary is on long-term effects, long-term use, and psychotherapeutic application of supervised disulfiram.
METHODS: A brief qualitative overview is given of previous and recent clinical studies on disulfiram in alcoholism treatment.
RESULTS: The alcohol deterrent disulfiram is an effective pharmacological adjunct to the treatment of AUD when it is administered as supervised low-dose disulfiram and is integrated in comprehensive biopsychosocial alcoholism therapy. However, the assumed underlying psychological effects of psychotherapeutic disulfiram application have never been properly investigated. Prospective long-term follow-up studies are rare and suggest that long-term effects of disulfiram are associated with long-term use and/or integration of the medication in cognitive behavior therapy.
CONCLUSIONS: Evidence from decades of research suggests psychological effects as principal mode of action of supervised disulfiram. Future randomized controlled trials are needed that investigate psychological actions and long-term outcomes of this alcohol deterrent.
Copyright © 2011 by the Research Society on Alcoholism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21569053     DOI: 10.1111/j.1530-0277.2011.01519.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  6 in total

1.  [Developmental process of DGPPN quality indicators].

Authors:  I Großimlinghaus; P Falkai; W Gaebel; B Janssen; D Reich-Erkelenz; T Wobrock; J Zielasek
Journal:  Nervenarzt       Date:  2013-03       Impact factor: 1.214

Review 2.  [Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].

Authors:  M Gahr; M A Kölle; C Schönfeldt-Lecuona
Journal:  Nervenarzt       Date:  2013-05       Impact factor: 1.214

Review 3.  Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.

Authors:  C E Van Skike; S E Maggio; A R Reynolds; E M Casey; M T Bardo; L P Dwoskin; M A Prendergast; K Nixon
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-11-12       Impact factor: 5.067

Review 4.  Use of pharmacotherapies in the treatment of alcohol use disorders and opioid dependence in primary care.

Authors:  Jinhee Lee; Thomas F Kresina; Melinda Campopiano; Robert Lubran; H Westley Clark
Journal:  Biomed Res Int       Date:  2015-01-05       Impact factor: 3.411

5.  Two-year prognosis after residential treatment for patients with alcohol dependence: three chief guidelines for sobriety in Japan.

Authors:  Tetsuji Cho; Hideki Negoro; Yasuhiro Saka; Masayuki Morikawa; Toshifumi Kishimoto
Journal:  Neuropsychiatr Dis Treat       Date:  2016-08-05       Impact factor: 2.570

Review 6.  [Pharmacotherapy of alcohol withdrawal: update and new developments].

Authors:  Michael Soyka; Susanne Rösner
Journal:  Nervenarzt       Date:  2021-01       Impact factor: 1.214

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.